DEA Schedule III Hearing Looms: What the June 2026 Rescheduling Means

The Biggest Federal Cannabis Hearing in Decades Is Weeks Away

The cannabis industry is holding its collective breath as the Drug Enforcement Administration prepares for what could be the most consequential federal hearing on marijuana policy in modern history. Beginning June 29, 2026, at the DEA Hearing Facility in Arlington, Virginia, administrative law judges will weigh evidence on whether marijuana should be broadly rescheduled from Schedule I to Schedule III of the Controlled Substances Act.

The hearing, which is expected to run through July 15, arrives at a pivotal moment. In April 2026, the Justice Department already placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III through an expedited order. Now, the question before the DEA is whether that reclassification should extend to marijuana more broadly — a move that would fundamentally alter the regulatory, financial, and legal landscape for cannabis businesses and consumers nationwide.

How We Got Here: A Timeline of Federal Action

The path to the June hearing has been anything but straightforward. President Trump's December 2025 executive order directing the rescheduling of marijuana set the machinery in motion, but it was the Justice Department's April 2026 order that delivered the first concrete results. That order accomplished two things simultaneously: it immediately moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III, and it initiated the formal administrative hearing process for broader rescheduling.

The DOJ's dual-track approach was deliberate. By moving state-licensed medical cannabis to Schedule III immediately, the government provided relief to roughly 40 state medical marijuana programs and their licensees without waiting for the lengthier formal rulemaking process. California alone rushed to issue emergency regulations so that its approximately 1,600 state licensees could pursue DEA registration before critical deadlines.

What Schedule III Actually Means for the Industry

The practical implications of Schedule III classification are enormous. Under Schedule I, cannabis businesses have been unable to deduct ordinary business expenses under Section 280E of the Internal Revenue Code, resulting in effective tax rates that sometimes exceeded 70 percent. Schedule III would eliminate that burden, potentially saving the industry billions of dollars annually.

Beyond taxation, Schedule III status would open the door to federally recognized medical research, allow cannabis companies to access banking services more freely, and potentially enable interstate commerce for licensed operators. It would also permit physicians to prescribe marijuana products in a manner more consistent with other Schedule III substances such as ketamine, testosterone, and certain codeine formulations.

However, Schedule III does not mean legalization. Recreational marijuana programs operating under state law would still technically exist in conflict with federal law, even if enforcement priorities were to shift. The hearing will not address full descheduling or legalization — those remain legislative questions for Congress.

Who Is Participating and What to Expect

The May 28 deadline for parties to file written notice of intent to participate in the hearing is fast approaching. Industry groups, advocacy organizations, law enforcement associations, pharmaceutical companies, and public health organizations are all expected to present testimony.

Key participants likely include the Marijuana Policy Project, the National Organization for the Reform of Marijuana Laws, representatives from state cannabis regulatory agencies, and potentially representatives from the pharmaceutical industry who have invested in cannabis-derived therapeutics. On the opposing side, some law enforcement organizations and anti-legalization groups are expected to argue that broader rescheduling could undermine public safety.

The hearing format is a formal administrative proceeding, meaning evidence will be presented under oath, witnesses will be subject to cross-examination, and the administrative law judge will issue findings of fact and conclusions of law. This process is far more rigorous than a public comment period and could produce a detailed evidentiary record that shapes cannabis policy for years to come.

State-Level Ripple Effects Are Already Underway

States are not waiting for the hearing's outcome to begin adjusting their regulatory frameworks. California's emergency regulations for DEA registration represent just one example of proactive state action. Pennsylvania's medical cannabis program, which recently crossed a cumulative $9.1 billion in sales with over 438,000 active patients, is positioning itself to take full advantage of any federal relaxation.

Meanwhile, states with pending legalization efforts are watching closely. South Carolina has multiple bills in play that could establish a medical cannabis program, and Alabama is on the verge of seeing its first dispensaries open after years of delays following its 2021 medical marijuana legalization. A favorable hearing outcome could accelerate these state-level movements by reducing the political risk of supporting cannabis reform.

The Financial Stakes Are Staggering

Cannabis industry analysts estimate that the broader rescheduling could unlock tens of billions of dollars in value across the sector. The elimination of 280E tax penalties alone could double or triple the profitability of many cannabis operators. Access to traditional banking services would reduce the security risks and operational costs associated with running cash-intensive businesses.

Public cannabis companies have already seen stock price movements in anticipation of rescheduling. Cronos Group recently reported record first-quarter revenue of $45.2 million, a 40 percent year-over-year increase, partly fueled by investor optimism around federal policy changes. The broader cannabis stock indices have shown increased volatility as the hearing date approaches.

What Happens After the Hearing

The administrative law judge's decision after the hearing is not self-executing. The judge will issue a recommended decision, which the DEA Administrator will then review. The Administrator can accept, modify, or reject the recommendation. If the Administrator decides to proceed with rescheduling, a final rule would be published in the Federal Register, potentially subject to additional public comment.

The entire process could take months or even years to reach a final resolution. However, the fact that the DOJ has already placed certain marijuana products in Schedule III through an expedited order suggests that the current administration is motivated to see the process through relatively quickly.

What This Means for Cannabis Consumers and Patients

For patients, broader Schedule III status could mean greater access to cannabis-based therapies, more insurance coverage options, and a wider range of FDA-regulated products. Medical research, long hampered by Schedule I restrictions, could accelerate dramatically, leading to better understanding of dosing, drug interactions, and therapeutic applications.

For recreational consumers, the hearing's impact will be more indirect. While Schedule III status would not legalize recreational use at the federal level, it could reduce the stigma associated with cannabis and create a more favorable political environment for future legislative action.

The June 29 hearing represents a turning point — not the end of the journey, but a critical waypoint in the decades-long effort to align federal marijuana policy with the reality of a multi-billion-dollar industry serving millions of Americans across dozens of states.

Want to find a licensed dispensary near you? Browse Budpedia's cannabis dispensary directory — 7,400+ verified retailers with menus, deals, and hours across every legal state.